Marinus Pharmaceuticals Inc MRNS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRNS is a good fit for your portfolio.
News
-
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
-
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
-
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Marinus Gets FDA Orphan Designation for Ganaxolone in Lennox-Gastaut Syndrome
Trading Information
- Previous Close Price
- $1.20
- Day Range
- $1.16–1.54
- 52-Week Range
- $1.11–11.26
- Bid/Ask
- $1.44 / $1.45
- Market Cap
- $79.10 Mil
- Volume/Avg
- 68,530 / 1.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.08
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 166
- Website
- https://www.marinuspharma.com
Comparables
Valuation
|
Metric
|
MRNS
|
PLRX
|
ICVX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.91 | 1.63 | 3.30 |
Price/Sales | 2.08 | 477.92 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
MRNS
PLRX
ICVX
Financial Strength
|
Metric
|
MRNS
|
PLRX
|
ICVX
|
|---|---|---|---|
Quick Ratio | 3.79 | 17.43 | 17.59 |
Current Ratio | 4.07 | 17.72 | 18.06 |
Interest Coverage | −7.94 | −145.34 | — |
Quick Ratio
MRNS
PLRX
ICVX
Profitability
|
Metric
|
MRNS
|
PLRX
|
ICVX
|
|---|---|---|---|
Return on Assets (Normalized) | −59.45% | −22.68% | −29.30% |
Return on Equity (Normalized) | −195.80% | −24.50% | −31.87% |
Return on Invested Capital (Normalized) | −84.00% | −28.46% | −34.69% |
Return on Assets
MRNS
PLRX
ICVX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Txqkbmshvl | Dssv | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rdzsksh | Hdtlxr | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tmkphvzpv | Gsgxs | $98.9 Bil | |
MRNA
| Moderna Inc | Kmxgwdbtn | Sgz | $39.7 Bil | |
ARGX
| argenx SE ADR | Zfzrccpr | Wnb | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Slqhqnxy | Mjp | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yhnwxrvj | Xvhmgjn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gykthrn | Ldfykdh | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lgpdwkmms | Wptqblv | $12.3 Bil | |
INCY
| Incyte Corp | Fqwzqtk | Mplmmqw | $11.8 Bil |